WO2023018342A1 - Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application - Google Patents

Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application Download PDF

Info

Publication number
WO2023018342A1
WO2023018342A1 PCT/PL2022/050050 PL2022050050W WO2023018342A1 WO 2023018342 A1 WO2023018342 A1 WO 2023018342A1 PL 2022050050 W PL2022050050 W PL 2022050050W WO 2023018342 A1 WO2023018342 A1 WO 2023018342A1
Authority
WO
WIPO (PCT)
Prior art keywords
rgo
hybrids
obtaining
application
graphene oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2022/050050
Other languages
French (fr)
Inventor
Magdalena GORSKA-PONIKOWSKA
Ludwika Lipinska
Joanna GIERALTOWSKA
Magdalena Baran
Adrian CHLANDA
Krystian Kowiorski
Lucyna KONIECZNA
Mariusz BELKA
Anna KAMM
Alicja KUBAN-JANKOWSKA
Jacek GULCZYNSKI
Ewa IZYCKA-SWIESZEWSKA
Narcyz KNAP
Aleksander ZOLNIERSKI
Tomasz BACZEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instytut Nauk Ekonomicznych Pan
Medical University of Gdańsk
Lukasiewicz Research Network - Institute of Microelectronics and Photonics
Original Assignee
Instytut Nauk Ekonomicznych Pan
Medical University of Gdańsk
Lukasiewicz Research Network - Institute of Microelectronics and Photonics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Nauk Ekonomicznych Pan, Medical University of Gdańsk, Lukasiewicz Research Network - Institute of Microelectronics and Photonics filed Critical Instytut Nauk Ekonomicznych Pan
Priority to EP22856321.9A priority Critical patent/EP4384222A4/en
Publication of WO2023018342A1 publication Critical patent/WO2023018342A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the GO-2-ME or rGO-2-ME hybrids which represent stable bonding of 2-methoxyestradiol (2-ME) molecules with graphene oxide GO or reduced graphene oxide rGO, the method of obtaining them, and their application as an anti-cancer drug.
PCT/PL2022/050050 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application Ceased WO2023018342A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22856321.9A EP4384222A4 (en) 2021-08-13 2022-08-12 GO-2-ME and RGO-2-ME hybrids, methods for their production and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL438737A PL243445B1 (en) 2021-08-13 2021-08-13 GO-2-ME and rGO 2-ME hybrids, method of their preparation and application
PLP.438737 2021-08-13

Publications (1)

Publication Number Publication Date
WO2023018342A1 true WO2023018342A1 (en) 2023-02-16

Family

ID=85200946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2022/050050 Ceased WO2023018342A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application

Country Status (3)

Country Link
EP (1) EP4384222A4 (en)
PL (1) PL243445B1 (en)
WO (1) WO2023018342A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4686473A1 (en) * 2024-07-30 2026-02-04 Gdanski Uniwersytet Medyczny Pharmaceutical composition, pharmaceutical composition formulation and their use in the treatment of skin cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450037A1 (en) * 2024-10-15 2026-04-20 Wojskowa Akademia Techniczna Im. Jarosława Dąbrowskiego Graphene oxide suspension for aerosol administration and its application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NEWMAN SIMON P., FOSTER PAUL A., STENGEL CHLOE, DAY JOANNA M., HO YAIK T., JUDDE JEAN-GABRIEL, LASSALLE MYRIAM, PREVOST GREGOIRE, : "STX140 Is Efficacious In vitro and In vivo in Taxane-Resistant Breast Carcinoma Cells", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, no. 2, 15 January 2008 (2008-01-15), US, pages 597 - 606, XP093035850, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1717 *
See also references of EP4384222A4 *
TING ZHOU ET AL.: "Controlled release of doxorubicin from graphene oxide based charge-reversal nanocarrier", BIOMATERIALS, vol. 35, no. 13, April 2014 (2014-04-01), pages 4185 - 94, XP028668191, DOI: 10.1016/j. biomaterials . 2014.01.04 4 *
X.C. QIN ET AL.: "Folic acid-conjugated graphene oxide for cancer targeted chemophotothermal therapy", J PHOTOCHEM PHOTOBIOL B, vol. 120, 5 March 2013 (2013-03-05), pages 156 - 62, XP028524919, DOI: 10.1016/j.jphotobiol. 2012.12.00 5 *
YAO LV ET AL.: "Targeted delivery and controlled release of doxorubicin into cancer cells using a multifunctional graphene oxide", MATER SCI ENG C MATER BIOL APPL, vol. 59, February 2016 (2016-02-01), pages 652 - 660, XP029329685, DOI: 10.1016/j.msec. 2015.10.06 5 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4686473A1 (en) * 2024-07-30 2026-02-04 Gdanski Uniwersytet Medyczny Pharmaceutical composition, pharmaceutical composition formulation and their use in the treatment of skin cancer

Also Published As

Publication number Publication date
PL438737A1 (en) 2023-02-20
EP4384222A1 (en) 2024-06-19
EP4384222A4 (en) 2026-05-20
PL243445B1 (en) 2023-08-28

Similar Documents

Publication Publication Date Title
EP4434530A3 (en) Vcn enhancer compositions and methods of using the same
WO2017127807A8 (en) Crystal structure of crispr cpf1
EP4556069A3 (en) Modulators of sestrin-gator2 interaction and uses thereof
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
CR20200192A (en) Methods and compositions for nucleoside triphosphate and ribonucleic acid production
EP4582134A3 (en) Variable-stiffness distal extension for a blood pump system
EP4385514A3 (en) Formulations
EP4361261A3 (en) Novel cas13b orthologues crispr enzymes and systems
MX2024008464A (en) Antibody drug conjugates (adcs) having enzymatically cleavable groups.
WO2017049227A3 (en) Wedge dissectors for a medical ballon
EP4733325A3 (en) Multi-specific wnt surrogate molecules and uses thereof
EP3396532A3 (en) Dynamic precision for neural network compute operations
EP3990028A4 (en) Micellar nanoparticles and uses thereof
CN107428652A8 (en) For treating compound, composition and the method for inflammatory disease, degenerative disease and nerve degenerative diseases
EP4628063A3 (en) Modular exoskeleton for example for spinal cord injured patients
WO2016014342A3 (en) Ang-(1-7) derviative oligopeptides and methods for using and producing the same
WO2017079005A8 (en) Orthopedic fastener, retainer, and guide
EP4384222A1 (en) Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application
WO2017087916A3 (en) Thermostable glucose biosensors and uses thereof
EP4069987A4 (en) Flanged bearing, assembly, and method of making and using the same
WO2018183182A8 (en) Methods and compositions for reduction of immunogenicity
WO2018189661A3 (en) Methods and compounds for treating diabetes
WO2020109620A3 (en) Bacterial strains for medical uses
EP4321219A3 (en) Antibodies against lif and uses thereof
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856321

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022856321

Country of ref document: EP

Effective date: 20240313